about
Oral insulin delivery: how far are we?Probing insulin bioactivity in oral nanoparticles produced by ultrasonication-assisted emulsification/internal gelation.Co-encapsulation of lyoprotectants improves the stability of protein-loaded PLGA nanoparticles upon lyophilization.Effect of the Freezing Step in the Stability and Bioactivity of Protein-Loaded PLGA Nanoparticles Upon Lyophilization.Natural extracts into chitosan nanocarriers for rosmarinic acid drug delivery.How to overcome the limitations of current insulin administration with new non-invasive delivery systems.Polymer-based nanoparticles for oral insulin delivery: Revisited approaches.Oral films as breakthrough tools for oral delivery of proteins/peptides.Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery.Exploitation of lipid-polymeric matrices at nanoscale for drug delivery applications.Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy?Chitosan-based nanoparticles as delivery systems of therapeutic proteins.A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles.Polyester-Based Nanoparticles for the Encapsulation of Monoclonal Antibodies.Polyester-Based Nanoparticles for Delivery of Therapeutic Proteins.Annealing as a tool for the optimization of lyophilization and ensuring of the stability of protein-loaded PLGA nanoparticles.Solid state formulations composed by amphiphilic polymers for delivery of proteins: characterization and stability.Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles.Development, characterization, antioxidant and hepatoprotective properties of poly(Ɛ-caprolactone) nanoparticles loaded with a neuroprotective fraction of Hypericum perforatum.Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticlesOptimization of two biopolymer-based oral films for the delivery of bioactive moleculesCorrigendum to “Polymer-based nanoparticles for oral insulin delivery: Revisited approaches”,[Biotechnol Adv. 2015 Nov 1;33 (6 Pt 3):1342–54]Characterization of solid lipid nanoparticles produced with carnauba wax for rosmarinic acid oral deliveryEffect of lipid matrix on structure and stability of protein-loaded solid lipid nanoparticles and nanostructured lipid carriersEvaluation of the interactions between rosmarinic acid and bovine milk caseinThe impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epitheliumChitosan-Coated Solid Lipid Nanoparticles for Insulin DeliveryChitosan-coated solid lipid nanoparticles enhance the oral absorption of insulinAnticancer Activity of Rutin and Its Combination with Ionic Liquids on Renal CellsCytotoxicity and Chemotherapeutic Potential of Natural Rosin Abietane Diterpenoids and their Synthetic DerivativesNovel and revisited approaches in nanoparticle systems for buccal drug deliveryIonic Liquid-Polymer Nanoparticle Hybrid Systems as New Tools to Deliver Poorly Soluble DrugsA Brief Overview of the Oral Delivery of Insulin as an Alternative to the Parenteral Delivery
P50
Q24632900-5D756F66-339B-4450-92AA-E2FD746923B6Q30379795-3A428C76-4A6E-47FC-B951-15D8393EF64BQ30380354-64F1C5C8-30EC-41F8-91E9-3BA6D2BE7FFDQ30390835-19127C02-5C68-47E4-9BF4-14B15BC1CC11Q35502502-B8533EDA-F9F5-49FB-8284-3ACD12F822F8Q38309884-D45BF4BE-9CF4-48F5-BCA2-B1FAB9FC0AB6Q38366445-AA7FE150-CA2F-4A59-8B5E-DCC770ABBDBAQ38483273-5794BB65-81F3-4010-B713-F9140F9FCD95Q38709888-0201CBAC-5562-4D42-A928-E43C25865AC6Q38816436-2C7BE022-1086-4CF9-8ADF-65DB90198B9AQ39049314-D5643E6F-659B-4A76-BB50-8503B45135C7Q39245809-E93CDE21-104D-487D-9F99-B5E91DE8F6FBQ42198535-C30B0DCB-79BD-4A8A-B928-042CAE22C846Q47664243-46D3F4C3-834B-4522-962B-0EB9D61CA1C2Q47786761-43AB2F44-39EA-4392-B375-FA9551D3C795Q47880521-F77E8B20-CFC9-4F95-9F48-9D6E78EB942BQ47943533-1B73A75D-91A8-49BE-9AE7-F5CB378F5506Q48037729-38429D61-6232-442A-942D-E6E7E211B3A1Q50101504-E54B5C98-1348-4221-A7AC-AC7A71972AEDQ57095087-C2F48B56-102E-463A-88EB-0189D0095DF6Q57570651-622D1833-FA05-4E21-905D-AF0F08B0A6DDQ57570686-84CA7618-13B2-412D-B083-AF48A12450BDQ57570733-C4AE4505-EC09-49F8-967D-8558C4815322Q57570747-49A5FE0E-6562-4696-B37C-EA7846402A6BQ57570751-66950C59-C390-4A57-A20D-C9F66309BD62Q57570819-EB269B21-6D3C-4DC0-BBA0-351288AC4840Q57570847-277BF64F-2D8B-4169-B11D-E6DA8F3C8139Q57570886-CB2F963B-CD3A-4129-A558-E81379B06D6AQ89598052-79DFB915-C55D-42B2-B438-4412CD67B7B7Q91068751-C13155D0-95CF-4033-9539-C0EABC8C45BCQ92514879-4A668E93-0725-4C17-B979-7A7C8C982C8AQ92570846-B755AFF5-7BFD-45DB-86F6-D913556396B5Q92834381-F27AD0F4-85DD-4121-B5C0-3197071AB40E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pedro Fonte
@ast
Pedro Fonte
@en
Pedro Fonte
@es
Pedro Fonte
@nl
type
label
Pedro Fonte
@ast
Pedro Fonte
@en
Pedro Fonte
@es
Pedro Fonte
@nl
prefLabel
Pedro Fonte
@ast
Pedro Fonte
@en
Pedro Fonte
@es
Pedro Fonte
@nl
P106
P1153
55146900200
P21
P31
P496
0000-0002-1115-9282